Ascimib 40 MG
Product Name : Ascentib
Generic Name : Asciminib
Formulation :Tablet
Available Pack Size : 60’s Pot
Available Strengths : 40mg
Registrations : Bangladesh
Product Information
Ascimib (Asciminib) 40mg is a first-in-class STAMP inhibitor (Specifically Targeting the ABL Myristoyl Pocket) used to treat Philadelphia chromosome-positive Chronic Myeloid Leukaemia in chronic phase (Ph+ CML-CP), including newly diagnosed patients, previously treated patients, and those with the treatment-resistant T315I mutation. Unlike conventional ATP-competitive BCR-ABL tyrosine kinase inhibitors, Ascimib works by binding allosterically to the myristoyl pocket of the ABL1 protein, locking BCR-ABL1 in an inactive conformation through a mechanism entirely distinct from earlier TKIs, allowing it to remain active against many mutations that cause resistance to ATP-competitive inhibitors. Manufactured by Everest Pharmaceuticals Ltd., Bangladesh and globally supplied by Mediaid Pharmacy with worldwide shipping.
Basic Product Information of Ascimib (Asciminib) 40mg
| Brand Name | Ascimib (Asciminib) |
| Generic Name | Asciminib INN |
| Drug Class | STAMP Inhibitor (Allosteric BCR-ABL1 Inhibitor) |
| Available Strength | 40mg |
| Formulation | Film-Coated Tablet |
| Pack Size | 60 Tablets per Pot |
| Primary Indication | Philadelphia Chromosome-Positive CML in Chronic Phase, Including T315I-Mutated Disease |
| Regulatory Approvals | USFDA Approved (Newly Diagnosed and Previously Treated Ph+ CML-CP; T315I-Mutated Ph+ CML-CP). |
| Originator Brand | Scemblix by Novartis |
| Manufacturer | Everest Pharmaceuticals Ltd., Dhaka, Bangladesh |
| Global Supplier | Mediaid Pharmacy, Worldwide Shipping Available |
| Registration | Registered in Bangladesh |
| Storage Conditions | Store below 30 degrees Celsius. Keep in a dry place away from light and moisture. Keep out of the reach of children. |
How Ascimib (Asciminib) Works
Ascimib contains Asciminib, a first-in-class inhibitor that works by a fundamentally different mechanism than earlier BCR-ABL-targeted therapies. Conventional TKIs, such as imatinib, nilotinib, dasatinib, bosutinib, and ponatinib, are ATP-competitive inhibitors, meaning they compete with ATP at the kinase’s active site. Asciminib instead binds to the myristoyl pocket of the ABL1 protein, an entirely separate site, an approach known scientifically as a STAMP inhibitor (Specifically Targeting the ABL Myristoyl Pocket).
By binding this allosteric site, Ascimib stabilises BCR-ABL1 in an inactive conformation, switching off its abnormal signalling. Because this mechanism is distinct from ATP-competitive inhibition, Ascimib maintains activity against many BCR-ABL1 kinase domain mutations, including the T315I “gatekeeper” mutation, that cause resistance to ATP-competitive TKIs. In the pivotal ASCEMBL trial, Asciminib 40mg twice daily demonstrated statistically significant superiority over bosutinib in achieving major molecular response at 24 weeks in previously treated patients.
Ascimib is taken as an oral tablet on an empty stomach, and treatment is continued for as long as clinical benefit is observed.
Indications for Ascimib (Asciminib)
Ascimib (Asciminib) is indicated for the following conditions:
|
Newly Diagnosed or Previously Treated Ph+ CML-CP For adult patients with newly diagnosed Philadelphia chromosome-positive CML in chronic phase, and for adult patients with Ph+ CML-CP previously treated with two or more tyrosine kinase inhibitors. |
T315I-Mutated Ph+ CML-CP For adult patients with Ph+ CML-CP carrying the T315I mutation, a resistance mutation for which very few oral treatment options exist. |
Benefits of Ascimib (Asciminib) 40mg
|
First-in-Class Mechanism As the first approved STAMP inhibitor, Ascimib offers a genuinely new mode of action, distinct from every prior BCR-ABL TKI on the market. |
Proven Superiority Over Bosutinib The ASCEMBL trial demonstrated statistically significant superiority for major molecular response compared with bosutinib in heavily pre-treated patients. |
Effective Against Resistant Disease Ascimib’s distinct binding site allows it to remain active against many mutations, including T315I, that cause resistance to conventional ATP-competitive TKIs. |
|
Affordable Alternative to Scemblix Ascimib contains the same active ingredient as Scemblix by Novartis, at a significantly lower cost, making this precision therapy more financially accessible. |
Flexible Once- or Twice-Daily Dosing For standard CML dosing, Ascimib can be taken as 80mg once daily or 40mg twice daily, allowing the regimen to be tailored to the patient. |
WHO-GMP Certified Manufacturing Produced by Everest Pharmaceuticals Ltd. under WHO-GMP-compliant manufacturing standards, helping ensure consistent quality, purity, and potency in every batch of Ascimib tablets. |
How to Take Ascimib (Asciminib)
Route: Oral, taken on an EMPTY STOMACH. Avoid food for at least 2 hours before and 1 hour after each dose. Swallow tablets whole; do not break, crush, or chew.
Standard dose for newly diagnosed or previously treated Ph+ CML-CP: 80mg once daily (two 40mg tablets), or 40mg (one tablet) twice daily, continued for as long as clinical benefit is observed or until unacceptable toxicity.
Dose for T315I-mutated Ph+ CML-CP: 200mg twice daily, at least 12 hours apart. This higher dose requires a tablet strength beyond this 40mg product; please confirm the correct strength with your prescribing physician or supplier.
Missed dose: If a dose is missed, take it only if the next scheduled dose is more than a certain number of hours away, as advised by your physician; otherwise skip the missed dose and resume the normal schedule. Do not double up doses.
Dose modification for toxicity: Dose reduction in defined steps may be required to manage adverse reactions such as myelosuppression, pancreatitis, or hypertension, as directed by the prescribing physician.
Monitoring and Dosage Adjustments
Regular monitoring is essential throughout Ascimib treatment. Your haemato-oncologist will check complete blood counts regularly, particularly during the first few months, given the risk of thrombocytopenia, neutropenia, and anaemia. Monitoring also includes periodic lipase and amylase if pancreatitis is suspected, blood pressure, and BCR-ABL1 transcript levels to track molecular response to treatment. Report any unusual bruising or bleeding, fever, severe abdominal pain, chest pain, weakness or numbness on one side of the body, or signs of an allergic reaction (rash, swelling, difficulty breathing) to your doctor immediately.
Drug Interactions and Important Information
Use caution when combining Ascimib with medications that affect CYP3A4 or CYP2C9 metabolism, and inform your physician of your complete medication list before starting treatment. Avoid taking Ascimib with food, as this significantly affects absorption; consistently observe the 2-hour-before/1-hour-after food separation with every dose.
Inform your physician of any personal or family history of pancreatitis, cardiovascular disease, or blood clotting disorders before starting treatment. Women of childbearing potential should use effective contraception during treatment, as Ascimib may cause foetal harm. Always inform your physician of all medications, supplements, and herbal products you are currently taking before starting Ascimib.
Side Effects and Precautions
|
Common Side Effects Upper respiratory tract infections Musculoskeletal pain Fatigue and headache Nausea and diarrhoea Rash Abdominal pain |
Serious Warnings and Precautions Myelosuppression, including thrombocytopenia, neutropenia, and anaemia. Pancreatitis, including elevated lipase and amylase. Hypertension and arterial occlusive/cardiovascular events. Hypersensitivity reactions. Embryo-foetal toxicity. Not recommended during pregnancy or breastfeeding. |
Who Should Use Ascimib (Asciminib)?
Ascimib is suitable for adult patients with newly diagnosed Philadelphia chromosome-positive CML in chronic phase, patients with previously treated Ph+ CML-CP who have received two or more TKIs, and patients with T315I-mutated Ph+ CML-CP. It is prescribed by haemato-oncologists experienced in managing CML and interpreting BCR-ABL1 mutation testing. A thorough medical assessment including BCR-ABL1 mutation status, baseline blood counts, lipase/amylase, and cardiovascular risk evaluation is required before initiating treatment.
Manufacturer: Everest Pharmaceuticals Ltd.
Everest Pharmaceuticals Ltd. is a vertically integrated pharmaceutical company based in Dhaka, Bangladesh, focused on complex, technology-driven specialty medicines across oncology, nephrology, and virology. Operating under Bangladesh’s TRIPS/Doha Declaration exemption for least-developed countries, Everest manufactures advanced generics such as Ascimib under WHO-GMP-compliant standards, with the stated mission of making high-cost, life-saving medicines accessible and affordable to patients around the world. Ascimib is one of Everest’s specialty oncology products, offering a bioequivalent alternative to Scemblix by Novartis at a fraction of the cost.
Global Supplier: Mediaid Pharmacy with Worldwide Shipping
Mediaid Pharmacy is a trusted global supplier of specialty and oncology medications. We ensure Ascimib (Asciminib) is accessible to patients and healthcare providers worldwide through reliable worldwide shipping. Whether you are located in South Asia, the Middle East, Africa, Europe, or beyond, Mediaid Pharmacy provides fast and reliable delivery with full order support. Contact us directly via WhatsApp, phone, or WeChat for pricing, availability, and delivery enquiries.
Why Choose Ascimib (Asciminib) from Mediaid Pharmacy?
Ascimib represents a genuine mechanistic advance in CML treatment, offering an entirely new way of blocking BCR-ABL1 signalling. As the generic equivalent of Scemblix by Novartis, it delivers the same active ingredient, Asciminib, with the same proven STAMP-inhibition mechanism at a dramatically more affordable price. Manufactured by Everest Pharmaceuticals Ltd. under WHO-GMP-compliant standards and distributed globally by Mediaid Pharmacy, Ascimib gives patients worldwide access to this next-generation CML therapy without the financial burden of brand-name alternatives. For patients and physicians seeking a proven, affordable, and accessible Asciminib option with worldwide delivery, Ascimib from Mediaid Pharmacy is the trusted choice.
Frequently Asked Questions About Ascimib (Asciminib)
What is Ascimib (Asciminib) used for?
Ascimib (Asciminib) is used to treat adult patients with Philadelphia chromosome-positive Chronic Myeloid Leukaemia in chronic phase, whether newly diagnosed, previously treated with two or more TKIs, or carrying the treatment-resistant T315I mutation. It works by a unique mechanism, binding a different site on the BCR-ABL1 protein than earlier CML medicines.
How should I take Ascimib (Asciminib)?
Ascimib is taken orally on an empty stomach, avoiding food for at least 2 hours before and 1 hour after each dose. The standard dose is 80mg once daily or 40mg twice daily. Patients with T315I-mutated disease require a much higher dose (200mg twice daily), which typically needs a higher tablet strength. Always follow your haemato-oncologist’s exact instructions.
What strength is Ascimib available in?
Ascimib is available in a 40mg tablet, supplied in a pot of 60 tablets. This strength covers the standard CML dosing options; patients with T315I-mutated disease should confirm strength availability with their supplier.
Is Ascimib the same as Scemblix (Asciminib by Novartis)?
Yes. Ascimib is the generic equivalent of Scemblix. Both contain the same active ingredient, Asciminib, and work through the same STAMP-inhibition mechanism. Ascimib is manufactured by Everest Pharmaceuticals Ltd. in Bangladesh and offers the same clinical mechanism as Scemblix at a significantly lower cost.
What are the side effects of Ascimib (Asciminib)?
Common side effects include upper respiratory infections, musculoskeletal pain, fatigue, nausea, and rash. Serious but less common risks include low blood counts, pancreatitis, high blood pressure, and cardiovascular events. Always consult your haemato-oncology team for a complete assessment of your individual risks and benefits before starting treatment.
Can Ascimib be used with other medications?
Use caution combining Ascimib with medications that affect CYP3A4 or CYP2C9 metabolism. Avoid taking Ascimib with food, as this significantly reduces absorption. Always inform your physician of all medications, supplements, and herbal products you are taking before starting Ascimib.
Is Ascimib (Asciminib) safe during pregnancy or breastfeeding?
No. Ascimib is not recommended during pregnancy or breastfeeding, as it can cause foetal harm. Women of childbearing potential should use effective contraception during treatment. Please consult your physician before starting treatment if you are pregnant, planning to become pregnant, or breastfeeding.
Can I order Ascimib (Asciminib) online with worldwide shipping?
Yes. Mediaid Pharmacy supplies Ascimib (Asciminib) 40mg globally with worldwide shipping. Contact us via WhatsApp, phone, or WeChat at +8801773428128 or email us at info@mediaidpharmacy.com to enquire about pricing, availability, and delivery to your country.
Order Ascimib (Asciminib) 40mg with Worldwide Shipping
Phone / WhatsApp / WeChat: +8801773428128 | Email: info@mediaidpharmacy.com
